Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000 participants
OBSERVATIONAL
2016-01-31
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identify Prognostic Biomarkers of Lung Cancer
NCT05010330
CTC in Lung Caner Patients With Bone Metastases
NCT04568291
Precision Diagnosis for Intraoperative Frozen Section of Early Stage Lung Cancer
NCT02941003
Low-dose Protocol for Computed Tomography-guided Lung Biopsy
NCT02971176
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
NCT06255197
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Normal lung tissue
Normal lung tissue from LCLC patients
Normal lung tissue
The investigators will extract total protein, DNA and RNA from LCLC patients.
LCLC tissues
LCLC tissues from LCLC patients
Normal lung tissue
The investigators will extract total protein, DNA and RNA from LCLC patients.
Metastasis tissues
Metastasis tissues from LCLC patients
Normal lung tissue
The investigators will extract total protein, DNA and RNA from LCLC patients.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Normal lung tissue
The investigators will extract total protein, DNA and RNA from LCLC patients.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No severe major organ dysfunction
* World Health Organization (WHO) performance status of 0 or 1
* No prior cancer chemotherapy
Exclusion Criteria
* Severe major organ dysfunction
* WHO performance status of \>1
* Prior cancer chemotherapy
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Pulmonary Hospital, Shanghai, China
OTHER
Shanghai 10th People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Da Fu
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Da Fu, PhD
Role: PRINCIPAL_INVESTIGATOR
Shanghai 10th People's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ganzhou City People's Hospital
Ganzhou, Jiangxi, China
Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-52-Rainy
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.